Curated News
By: NewsRamp Editorial Staff
July 01, 2025
Nutriband Joins Russell Indexes, Highlighting AVERSA Fentanyl's Potential
TLDR
- Nutriband's inclusion in Russell indexes highlights its AVERSA Fentanyl's potential for $80M-$200M annual sales, offering investors a unique growth opportunity in the pharmaceutical sector.
- Nutriband Inc. leverages AVERSA technology in transdermal patches to deter drug abuse, with its fentanyl patch leading development and now recognized by Russell indexes.
- Nutriband's AVERSA technology aims to reduce drug abuse and accidental exposure, contributing to safer pharmaceutical solutions and a healthier society.
- Discover how Nutriband's innovative AVERSA technology is setting new standards in abuse-deterrent pharmaceuticals, now gaining recognition in prestigious Russell indexes.
Impact - Why it Matters
This news is significant as it highlights Nutriband's growing influence in the pharmaceutical sector, particularly in the development of abuse-deterrent technologies. The inclusion in the Russell indexes not only provides Nutriband with increased visibility among investors but also underscores the importance of innovative solutions to combat drug abuse and misuse. For the public, this means safer pharmaceutical options are on the horizon, potentially reducing the risks associated with opioid abuse. For investors, it represents an opportunity to be part of a company that's making strides in addressing a critical public health issue.
Summary
Nutriband Inc. (NASDAQ: NTRB), a company at the forefront of developing transdermal pharmaceutical products, has achieved a significant milestone by being added to several Russell indexes, including the Russell Microcap and Russell 3000E Growth Indexes. This inclusion, as part of the 2025 Russell indexes reconstitution, underscores the market's recognition of Nutriband's innovative AVERSA pipeline, particularly its AVERSA Fentanyl patch. CEO Gareth Sheridan highlighted the potential of AVERSA Fentanyl, projecting peak annual U.S. sales between $80 million and $200 million. The Russell indexes, managed by FTSE Russell, are pivotal in the investment world, benchmarking around $10.6 trillion in assets. Nutriband's AVERSA technology is designed to prevent the abuse and misuse of drugs with abuse potential, marking a significant advancement in pharmaceutical safety. For more details, visit https://ibn.fm/wa35e.
Nutriband's commitment to innovation is further detailed on their website, www.Nutriband.com, where investors and the public can learn more about their groundbreaking work. The newsroom at https://ibn.fm/NTRB offers the latest updates on NTRB, ensuring stakeholders are well-informed. This development not only highlights Nutriband's growth but also the broader potential of abuse-deterrent technologies in the pharmaceutical industry.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Nutriband Joins Russell Indexes, Highlighting AVERSA Fentanyl's Potential
